1. Home
  2. CHY vs EVO Comparison

CHY vs EVO Comparison

Compare CHY & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHY
  • EVO
  • Stock Information
  • Founded
  • CHY 2003
  • EVO 1993
  • Country
  • CHY United States
  • EVO Germany
  • Employees
  • CHY N/A
  • EVO N/A
  • Industry
  • CHY Investment Managers
  • EVO Biotechnology: Pharmaceutical Preparations
  • Sector
  • CHY Finance
  • EVO Health Care
  • Exchange
  • CHY Nasdaq
  • EVO Nasdaq
  • Market Cap
  • CHY 947.9M
  • EVO 1.1B
  • IPO Year
  • CHY N/A
  • EVO 2021
  • Fundamental
  • Price
  • CHY $12.20
  • EVO $5.35
  • Analyst Decision
  • CHY
  • EVO Buy
  • Analyst Count
  • CHY 0
  • EVO 2
  • Target Price
  • CHY N/A
  • EVO $5.90
  • AVG Volume (30 Days)
  • CHY 128.3K
  • EVO 378.7K
  • Earning Date
  • CHY 01-01-0001
  • EVO 11-06-2024
  • Dividend Yield
  • CHY 10.11%
  • EVO N/A
  • EPS Growth
  • CHY N/A
  • EVO N/A
  • EPS
  • CHY N/A
  • EVO N/A
  • Revenue
  • CHY N/A
  • EVO $866,665,179.00
  • Revenue This Year
  • CHY N/A
  • EVO $4.56
  • Revenue Next Year
  • CHY N/A
  • EVO $13.44
  • P/E Ratio
  • CHY N/A
  • EVO N/A
  • Revenue Growth
  • CHY N/A
  • EVO N/A
  • 52 Week Low
  • CHY $9.97
  • EVO $2.85
  • 52 Week High
  • CHY $12.16
  • EVO $12.00
  • Technical
  • Relative Strength Index (RSI)
  • CHY 55.34
  • EVO 65.10
  • Support Level
  • CHY $11.74
  • EVO $4.99
  • Resistance Level
  • CHY $12.37
  • EVO $5.64
  • Average True Range (ATR)
  • CHY 0.15
  • EVO 0.23
  • MACD
  • CHY 0.00
  • EVO 0.09
  • Stochastic Oscillator
  • CHY 70.18
  • EVO 85.13

About CHY Calamos Convertible and High Income Fund

Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high yield securities.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: